University Medical Center Hamburg-EppendorfGermany
Syed Hani Hassan Abidi is an Associate Professor at the Department of Biomedical Sciences , School of Medicine , Nazarbayev University , Kazakhstan. His research integrates virology , immunology , viral oncology , and bioinformatics , with a focus on HIV molecular epidemiology , viral evolution , and drug resistance . He has led international projects across Pakistan, Kenya, Afghanistan, and Kazakhstan, and is recognized for innovative teaching and MOOC development. Education: PhD in Virology and Immunology Research Interests: His laboratory employs bioinformatics (machine learning, AI), genomics , and proteomics to study HIV phylodynamics , viral co-infections , and oncogenic viruses like EBV in prostate cancer. He also explores microbiome-immunity interactions and designs antiviral drugs/vaccines . Recent Research Trends: His 2025 publications emphasize COVID-19 immunopathology , HIV/syphilis epidemiology in Pakistan , and particle physics contributions via ATLAS , showcasing interdisciplinary impact. Awards & Recognition: Outstanding Teachers Award (2019, Aga Khan University) Fellowship of Higher Education (UK, 2022) Teaching & Grants: He pioneered Pakistan’s first MOOC on Computer-Based Drug Discovery (2014) and received a 2022 SoTL grant for MOOC-based molecular biology education. His teaching integrates animations , films , and flipped classrooms . Collaborations & Labs: Leads projects on HIV drug resistance , HCV genomics in Kazakhstan , and AI-driven dementia diagnostics (Kazakh Brain Atlas). His lab collaborates with global institutions to advance viral disease surveillance and therapeutic innovation .
Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Dr. Oliver Krüger is a behavioral ecologist and evolutionary biologist at Bielefeld University 's Faculty of Biology , where he leads the Department of Animal Behaviour since 2013. His research spans avian and marine mammal systems, focusing on life history strategies, parasite-host interactions, and environmental adaptation. Education: Biology studies at Bielefeld University (1994-1996) MSc in Oxford (1996-1997) PhD at Bielefeld University with Fritz Trillmich and Jan Lindström (1998-2000) Research Themes: Behavioral ecology, evolutionary biology, and population dynamics across tropical and temperate ecosystems. Key projects include NC³ (Niche Choice/Construction) and studies on Galápagos sea lions, common buzzards, and pinniped species. Scientific Leadership: Spokesperson, SFB TRR 212 "NC³" (2018-2025) Advisory Board member: German Ornithologists Union, IUCN SSC pinniped group, German Primate Centre Peer review roles: Humboldt Foundation, DFG, HFSP, NSF Awards: Leopoldina Prize (2001) Niko Tinbergen Award (2008) DFG Heisenberg Professorship (2010-2015)
Prof. Ralph Hückelhoven is a Professor of Phytopathology at the Technical University of Munich (TUM), affiliated with the TUM School of Life Sciences. His research focuses on the molecular and biological mechanisms underlying plant diseases, particularly plant immunity, pathogen exploitation of signal transduction, and host-pathogen interactions. He leads the Chair of Phytopathology at TUM since 2006, following academic roles at universities of Kiel and Hohenheim. Education: PhD (1999) and habilitation in molecular phytopathology (2005) from Justus Liebig University Giessen, after a biology degree at RWTH Aachen University. Awards: Julius Kühn Prize (2004) and leadership of a DFG Junior Research Group (2002-2006). His research spans plant immunity at cellular and molecular levels, including studies on receptor kinases (e.g., MIK2, LORE), RAC GTPases (e.g., RACB), and metabolomics-driven insights into pathogen resistance. He has published over 100 peer-reviewed articles, examining topics like fungal toxins, volatile signaling, and crop disease management. Key publications include work on Arabidopsis immune receptors, barley powdery mildew susceptibility factors, and Fusarium head blight resistance. Research integrates genetics, proteomics, and metabolomics to advance disease-resistant crop development. His lab investigates host-pathogen interactions across scales—from molecular signaling to field epidemiology—contributing to sustainable agricultural strategies against plant pathogens.
Prof. Friederike Ebner holds the Chair of Infection Pathogenesis at the Technical University of Munich (TUM) since 2023, within the TUM School of Life Sciences. Her research focuses on the immunobiology of parasite infections, particularly studying gastrointestinal helminths like Ascaris suum and their interactions with host immune systems to design novel intervention strategies. She also develops biomedical models for studying infectious diseases. Educational Background: Friederike Ebner earned a biotechnology degree from TU Berlin and Dongseo University (South Korea). She completed her PhD in biology at Humboldt University Berlin (2014), followed by postdoctoral research in immunology at Freie Universität Berlin, where she became an assistant professor before moving to TUM. Research Interests: Her work spans helminth-host immune dynamics, vaccine development, microbiome interactions in parasitic infections, and translational models for human diseases. Key topics include Th2/Th1 immune balance, helminth-derived immunomodulators, and xenotransplantation safety. Notable Contributions: Her recent studies address diagnostic methods for ascariasis, microbiome roles in helminth survival, and immunotherapeutic applications of parasite products. Current efforts emphasize bridging fundamental immunology with clinical and veterinary applications. Professional Activities: Prof. Ebner teaches immunology and parasite biology at TUM while maintaining active collaborations in global health and infectious disease research. She advocates for interdisciplinary approaches to address knowledge gaps in parasitology and vaccinology.
Prof. Dr. Michael Schloter serves as Director of the Research Unit for Comparative Microbiome Analysis at Helmholtz Munich since 2011 and holds a Professorship in Microbiology at the Technical University of Munich since 2010. He concurrently acts as Principal Investigator at both the German Center for Lung Diseases (DZL) and the Central for Food and Nutrition (ZIEL) at TU Munich, driving interdisciplinary research at the intersection of environmental and human health through the "Planetary Health" framework. His educational foundation was built through diploma studies at Ludwig Maximilian University Munich and doctoral research at the University of Bayreuth, followed by formative work in Brazil and the United States where he pioneered bioinocula development for stress-resilient agriculture. At Helmholtz Munich (formerly GSF), he evolved from group leader in soil microbial ecology (2001) to Research Unit Director, expanding his focus from agricultural systems to human microbiome-health connections. Dr. Schloter's research program centers on microbiome-host crosstalk across ecological scales, investigating how environmental microbiota interact with human and plant microbiomes to influence health outcomes. His work integrates ecological theory with microbiome analysis to decode host-microbe co-evolution patterns, with applications spanning sustainable agriculture, allergy prevention, and infection control. Key thematic pillars include holobiont theory, probiotic development, and microbiome-mediated disease prevention through environmental quality improvement. Analysis of his 2025 publications reveals a strategic research portfolio bridging fundamental and applied microbiome science. Agricultural studies dominate (maize, potato, apple systems), examining microbial inoculants and soil management, while human health investigations explore preterm birth complications and Antarctic mammal microbiomes. Computational approaches for antimicrobial resistance assessment and ecosystem-scale projects like JenaTron demonstrate methodological breadth, all converging on translating microbiome functionality into real-world sustainability solutions. Major recognitions include: Election to the Bavarian Academy of Science (2021) Consistent placement among the top 1% of highly cited global researchers (2019-2021) Heinrich Baur Research Award (2011) for agricultural microbiology contributions As Research Unit Director, Schloter leads large-scale collaborative initiatives including the DZL and ZIEL consortia, securing major funding for microbiome standardization projects and international research networks. His leadership extends to developing analytical frameworks for cross-ecosystem microbiome comparisons and establishing protocols for translating microbial ecology principles into clinical and agricultural applications. The Comparative Microbiome Analysis unit operates as a nexus for multi-host microbiome research, employing comparative genomics, field-scale agricultural trials, and clinical cohort studies to investigate microbiome dynamics across environmental, plant, and human systems. Current infrastructure includes advanced sequencing facilities and experimental platforms for plant-microbe and host-microbe interaction studies under controlled and natural conditions.
Prof. Dr. Kathrin Schumann is an Assistant Professor at the Technical University of Munich (TUM), leading the 'Engineering Immune Cells for Therapy' group within the TUM School of Medicine and Health. Her research focuses on CRISPR-based engineering of human immune cells to develop novel therapies for autoimmune and tumor diseases. She holds a doctorate from the Max Planck Institute of Biochemistry and has conducted postdoctoral research at the University of California, San Francisco, under Professors Alex Marson and Jeffrey Bluestone. Dr. Schumann’s academic career includes a Presidential Postdoc Fellowship at Novartis (Basel) and a tenure-track appointment at TUM since 2018. Her work emphasizes genomic editing of T cells to study gene function and improve cell therapy safety. Key research themes include CRISPR-mediated gene silencing, T cell receptor engineering, and HIV-host interaction studies. Education: Bachelor/Master in Biochemistry, University of Tübingen PhD, Max Planck Institute of Biochemistry (Martinsried) Postdoc, University of California, San Francisco (UCSF) Her research has yielded breakthroughs in CRISPR applications for T cell therapy, including PD-1 disruption to enhance anti-tumor efficacy and targeted editing of T cell receptors. Awards include a DFG research grant (2016). Notable achievements include the development of CRISPR ribonucleoprotein platforms for primary T cells and insights into metabolic checkpoints in T cell exhaustion. Her lab collaborates globally to translate CRISPR-based discoveries into clinical therapies.
Prof. Dr. Florian Jeltsch leads the Plant Ecology and Nature Conservation research group at the Institute of Biology and Biochemistry, University of Potsdam. His work spans multiple ecological domains with a focus on understanding biodiversity patterns and processes in changing environments. His research group investigates community ecology across various landscapes including grasslands, agricultural systems, and drylands. Dr. Jeltsch's research interests encompass Community Ecology of Grasslands and Agricultural Landscapes, Community Ecology of Drylands, Biodiversity in Heterogeneous Environments, Movement Ecology and Biodiversity Dynamics, and Applied Regional Conservation. His work integrates theoretical and empirical approaches to address pressing ecological questions related to global change. He has been instrumental in developing and applying individual-based models to understand complex ecological systems. Analysis of Dr. Jeltsch's recent publications reveals a strong focus on individual-based ecological modeling, movement ecology, and the impacts of landscape heterogeneity on biodiversity. His work spans from theoretical foundations to practical conservation applications, with particular emphasis on savanna ecosystems, habitat fragmentation effects, and climate change impacts. The research demonstrates integration of multiple scales from individual energetics to community dynamics. Dr. Jeltsch has mentored numerous doctoral students and postdoctoral researchers who have gone on to establish their own research careers. His group has been involved in multiple collaborative projects including BioHet, GrassYear, BioMove, and ORYCS, addressing biodiversity conservation in heterogeneous environments. The Plant Ecology and Nature Conservation group maintains active research stations including the Gülpe Research Station, providing field-based research opportunities. The group's work bridges theoretical ecology with practical conservation applications, particularly in the context of global environmental change.
Martin Kaltenpoth serves as Director at the Max Planck Institute for Chemical Ecology in Jena since 2020 and Professor for Evolutionary Ecology at Johannes Gutenberg University of Mainz since 2015. Previously, he led the Research Group Insect Symbiosis at the MPI for Chemical Ecology from 2009 to 2015. Education: PhD in Biology (summa cum laude), University of Würzburg, 2006 Diploma in Biology (with honors), University of Würzburg, 2003 His research centers on insect-bacterial symbioses , investigating evolutionary, ecological, and chemical dimensions of host-microbe interactions. Key foci include nutritional and defensive symbiosis in beetles, genomic adaptations of symbiotic bacteria, and chemical mediation of symbiotic relationships. His work bridges entomology, microbiology, and chemical ecology to unravel coevolutionary mechanisms. Analysis of recent publications reveals dominant trends in beetle-microbe systems, emphasizing symbiont roles in cuticle synthesis, antifungal defense, and host-plant adaptation. His studies frequently employ genomic, biochemical, and experimental approaches across diverse insect lineages. No scientific awards were documented in the source material. While specific advisees and grants remain unlisted, his leadership of research groups and dual academic appointments indicate active supervision of graduate researchers and externally funded projects in symbiosis evolution. Currently directing research at the Max Planck Institute, Kaltenpoth advances understanding of symbiotic systems with implications for evolutionary theory and sustainable pest management strategies.
Leibniz Institute for Zoo and Wildlife ResearchGermany
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
Professor Stephan A. Sieber is a leading researcher in bioorganic chemistry at the Technical University of Munich (TUM), where he holds the Chair of Organic Chemistry II within the TUM School of Natural Sciences. His research program focuses on developing new drugs against multidrug-resistant bacteria through a multi-disciplinary approach that integrates synthetic chemistry, functional proteomics, microbiology, and protein biochemistry. His laboratory has made significant contributions to identifying unprecedented antibacterial targets beyond the scope of current antibiotics and exploiting these for chemical manipulation. Recent work has increasingly incorporated machine learning approaches to accelerate antibiotic discovery, with notable publications on AI-guided pipelines, drug-target interaction prediction, and high-throughput screening optimization. Sieber's research has resulted in the discovery of new active substances, some of which are currently being optimized for medical applications. His group's publications reveal a strong focus on chemical proteome mining, natural product mode of action studies, and novel antibacterial target identification. The lab has published extensively in top journals including Nature Chemistry, Nature Communications, and ACS Central Science. Inhoffen Medal (2024) Max Bergmann Medal (2023) ERC Advanced Grant (2023) Merck Future Insight Prize (2020) Klaus Grohe Prize (2020) ERC Consolidator Grant (2016) Professor Sieber leads an active research group that maintains a strong presence in the scientific community through regular publications, conference presentations, and collaborations. His laboratory website and BlueSky presence (@sieberlab.bsky.social) demonstrate ongoing research activities and engagement with the broader scientific community. He has successfully secured significant research funding including multiple ERC grants that have supported his innovative work in antibiotic discovery.
Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.
Prof. Dr. Jörg Stülke is a full Professor of Microbiology and Head of the Department of General Microbiology at the Institute of Microbiology and Genetics, University of Göttingen. He has held this position since 2003 and leads an active research group focused on bacterial metabolism and gene regulation. His research spans two major model systems: the pathogenic bacterium Mycoplasma pneumoniae and the well-studied Bacillus subtilis . His group employs systems-level approaches including transcriptomics, metabolomics, and bioinformatics to understand metabolic regulation and gene expression. Key interests include protein phosphorylation, RNA-mediated regulation, mRNA processing, and the role of second messengers such as cyclic di-AMP in bacterial physiology and pathogenicity. The recent publications reveal a strong trend in molecular microbiology, functional genomics, and systems biology. His work often integrates experimental and computational methods, particularly evident in the development and maintenance of the SubtiWiki database for B. subtilis . The research bridges fundamental mechanisms of life with applications in understanding bacterial virulence and cellular homeostasis. He is affiliated with several graduate programs under the Göttingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB), including: Molecular Biology (IMPRS) Biomolecules: Structure - Function - Dynamics (GZMB) Molecular Biology of Cells (GZMB) Microbiology and Biochemistry Genome Science (IMPRS) While no individual students are listed, he clearly supervises doctoral candidates through these programs. His group has secured significant research output, including publications in Science , Nucleic Acids Research , and PLOS Pathogens , indicating successful grant funding and collaborative research. The lab maintains a dedicated website at http://genmibio.uni-goettingen.de/ , which serves as a hub for research activities and resources like SubtiWiki.
Ralf Zimmer is a Full Professor for Practical Informatics and Bioinformatics at Ludwig Maximilian University of Munich (LMU) since 2001, affiliated with the Department of Informatics in the Faculty of Mathematica, Informatics and Statistics. He concurrently serves as Head of Section III and Head of the Research Group Network Regulation and Modeling / Machine Learning at the Leibniz Institute for Food Systems Biology at TUM (Leibniz-LSB@TUM) in Freising, Germany. His academic foundation includes a Diploma with distinction in Computer Science, Applied Mathematics and Operations Research from the University of Bonn (1981-1986), followed by a summa cum laude Doctorate in Computer Science and Applied Mathematics from CAU Kiel in 1990, where he received dual honors: the CAU Dissertation Award and Best Dissertation Award. Zimmer's research pioneers the integration of bioinformatics, systems biology, and machine learning to decode molecular food-consumer interactions. His group develops causal system models for biological networks, validated through in silico simulations and multi-omics perturbation experiments (transcriptomics/proteomics). Core methodologies include network regulation modeling, algorithmic bioinformatics, and database construction linking food compounds to biochemical networks and cellular phenotypes, with translational goals for food and biotech innovation. His 14 most recent publications (2012-2024) reveal dominant trends in multi-omics immunology and cardiovascular research, featuring computational innovations for high-throughput data analysis. Key themes include host-pathogen dynamics (viral infections), inflammatory disease mechanisms (atherosclerosis), and methodological advances in proteomics/transcriptomics, consistently bridging fundamental bioinformatics with clinical applications. Major scientific recognitions include: CAU Dissertation Award and Best Dissertation Award (1990) Director of LMU's Informatics Department (2010-2012) DFG Review Board membership for biomedical foundations (2008-2016) Leadership of the DFG Bioinformatics Munich Center (2001-2008) Academic Senate election at LMU München (2011) Zimmer directs LMU/TUM's joint B.Sc./M.Sc. bioinformatics programs since 2001 as founding architect of the DFG-funded Bioinformatics Munich initiative. His educational leadership spans spokesperson roles for international training groups (IRTG RECESS), collaborative research centers (SFB1123 Atherosclerosis), and elite programs (Data Science, Munich Center for Machine Learning). Grant stewardship includes directing the DFG Bioinformatics Munich Center and shaping national funding policy via the DFG review board. At Leibniz-LSB@TUM, his research group pioneers databases connecting food compounds to cellular phenotypes through molecular networks, collaborating with Munich universities, clinics, and biotech partners to develop high-throughput sequencing/proteomics applications for future food and health innovations.
